IntraLase Receives Approval in Taiwan for Sales of Its FS Laser System; Company Plans Immediate Commercialization to Further Ex
29 Agosto 2006 - 10:00AM
Business Wire
IntraLase Corp. (NASDAQ:ILSE), manufacturer of the ultra-fast laser
that is revolutionizing refractive and corneal surgery, today
announced that Taiwan has granted approval for the sale of the
company's femtosecond laser in that nation. The company plans to
immediately commercialize the IntraLase(R) FS laser in Taiwan,
further expanding its global presence. As of June 30, 2006, 471
IntraLase lasers were installed around the world and over 850,000
IntraLase LASIK procedures had been performed in ophthalmic
practices worldwide. Taiwan Hwa-In, IntraLase's distributor in Hong
Kong and Mainland China, will begin offering the company's products
in Taiwan immediately. Mr. Jay Hsu, Chief Executive Officer of
Taiwan Hwa-In, stated, "The added safety of the IntraLase
Method(TM) in LASIK will provide excellent momentum to drive
patient demand in Taiwan, which has a very large number of patients
seeking safer and more reliable treatments." Mr. Hsu continued,
"Taiwan Hwa-In is a leader in the Taiwanese refractive market, with
over 20 years experience, and this approval allows us to help
doctors in Taiwan provide bladeless LASIK surgery to their
patients." "The Taiwanese market represents an exciting opportunity
and further demonstrates the global potential of IntraLase
technology," said Robert J. Palmisano, President and Chief
Executive Officer of IntraLase Corp. "We look forward to entering
this market and helping Taiwanese practitioners offer
clinically-proven safety and improved visual outcomes to their
patients." About IntraLase Corp. IntraLase designs, develops, and
manufactures an ultra-fast laser that is revolutionizing refractive
and corneal surgery by creating safe and more precise corneal
incisions. Delivering on the promise of ophthalmic laser
technology, the IntraLase FS laser, related software, and
disposable devices replace the hand-held microkeratome blade used
during LASIK surgery. The unsurpassed accuracy of IntraLase's
computer-controlled femtosecond laser has been shown to improve
safety profiles and visual outcomes when used during LASIK.
Additionally, the IntraLase FS laser creates precision-designed
intracorneal incisions that when combined can be used during
lamellar and penetrating keratoplasty, and intrastromal ring
implantation. IntraLase is presently in the process of
commercializing applications of its technology in the treatment of
corneal diseases that require corneal transplant surgery. The
company's proprietary laser and disposable patient interfaces are
presently marketed throughout the United States and 31 other
countries. IntraLase is headquartered and manufactures its products
in Irvine, California. For additional information, visit the
company's web site: www.intralase.com. Forward Looking Statements
Statements contained in this press release that are not historical
information are forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "anticipate," "intend," "plan," "estimate," "project," or
words of similar meaning, or future or conditional verbs such as
"will," "would," "should," "could," or "may." Such forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from those projected or
implied. Those risks and uncertainties include, but are not limited
to: the degree of continued acceptance of LASIK surgery; potential
complications revealed by long-term follow up; the extent of
adoption of our product offering by LASIK surgeons; general
economic conditions; changes in federal tax laws governing the
ability of potential LASIK patients to use pre-tax dollars to pay
for LASIK surgery; the scope of government regulation applicable to
our products; patients' willingness to pay for LASIK surgery; our
ability to compete against our competitors; the effectiveness of
our measures to ensure full payment of procedure fees; the
occurrence and outcome of product liability suits against us; our
ability to adequately protect our intellectual property; whether we
become subject to claims of infringement or misappropriation of the
intellectual property rights of others; the continued availability
of supplies from single-source suppliers and manufacturers of our
key laser components; the ability of our managers, operations, and
facilities to manage our growth; the success of our expansion into
markets outside the United States; whether we lose any of our key
executives or fail to attract qualified personnel; or if our new
products or applications fail to become commercially viable.
Certain of these risks and uncertainties, in addition to other
risks, are more fully described in the company's quarterly report
on Form 10-Q for the period ending June 30, 2006, as filed with the
Securities and Exchange Commission on August 1, 2006. These
forward-looking statements are made only as of the date of this
press release, and the company assumes no obligation to update or
revise the forward-looking statements, whether as a result of new
information, future events, or otherwise.
Intralase (NASDAQ:ILSE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Intralase (NASDAQ:ILSE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024